Published in Oncoimmunology on September 09, 2016
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol (2017) 1.05
Role of Distinct Natural Killer Cell Subsets in Anticancer Response. Front Immunol (2017) 0.75
NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology (2017) 0.75
NK Cell Exhaustion. Front Immunol (2017) 0.75
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (1998) 7.12
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A (1998) 3.35
Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med (1998) 2.87
MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol (2005) 2.08
NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood (2005) 1.78
HLA-E. A novel HLA class I gene expressed in resting T lymphocytes. J Immunol (1988) 1.73
TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity (2002) 1.39
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood (2010) 1.34
Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology (2000) 1.33
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.33
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med (1993) 1.20
Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer (1981) 1.16
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol (2015) 1.03
Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells. Int Immunopharmacol (2005) 0.98
Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1alpha to a distinct interferon-gamma-responsive element. J Biol Chem (1996) 0.97
Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants. Eur J Immunol (1998) 0.96
Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol (2012) 0.94
GATA-3 is an important transcription factor for regulating human NKG2A gene expression. J Immunol (2005) 0.93
Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR alphabeta lymphocytes. Eur J Immunol (2004) 0.93
The role of TCR stimulation and TGF-beta in controlling the expression of CD94/NKG2A receptors on CD8 T cells. Eur J Immunol (2005) 0.90
CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells. J Immunol (1999) 0.88
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res (2014) 0.87
Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens (2014) 0.86